Categories
Pharmaceutical

Demand For Colorectal Cancer Diagnostics Is Expected To Rise At A CAGR Of 8.5% Over The Decade

According to Fact.MR, a market research and competitive intelligence provider, the global colorectal cancer diagnostics market is anticipated to rise at a robust CAGR of 8.5% over the next ten years. As per this study, the market was valued at around US$ 2 Bn in 2020, and is anticipated to expand 2.2X by the end of the decade.

Incidence of colorectal cancer is increasing worldwide, and the World Health Organization (WHO) has predicted a rise of around 70% in cases by 2030. Increasing incidence of the disease can be attributed to factors such as poor lifestyle choices, unhealthy eating, aging, and diet-related disorders.

.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=70

The advent of new diagnostic tests, increasing uptakes of diagnosis-associated therapies, and initiatives taken by private as well as government organisations are some factors expected to propel growth of the global market for colorectal cancer diagnostics. Increasing unmet requirements across several emerging economies, coupled with the absence of neoadjuvant and adjuvant pipeline agents for diagnosing high-risk patients affected with resectable colorectal cancer is expected to create huge growth opportunities for leading players in the market. However, factors such as growing reluctance towards medications of colorectal cancer by patients, and unawareness across several remote regions of the globe is expected to inhibit the market growth.

6 Key Projections for the Global Colorectal Cancer Diagnostics Market

  • North America will continue to be the most lucrative region for the colorectal cancer diagnostics market. Revenue from market in North America is expected to surpass US$ 800 Mn by 2022-end.

For critical insights on this market, request for methodology here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=70

  • The colorectal cancer diagnostics market in Asia Pacific excluding Japan (APEJ) is expected to register the fastest expansion during the forecast period. However, revenue from the market in Middle East & Africa (MEA) will continue to be sluggish during the forecast period.
  • By test type, FOB will continue to be the largest adopted test for diagnosis of colorectal cancer across the globe. Revenue from FOB tests for colorectal cancer diagnostics will remain largest, followed by CTC tests.
  • Immunochemistry tests for colorectal cancer diagnostics will exhibit the highest CAGR through 2022. However, revenue from BRAF tests will remain the lowest in the global colorectal cancer diagnostics market during the forecast period.
  • On the basis of end-users, although hospital-associated labs will remain sought-after in the market, cancer research institutes will continue to register the fastest expansion during the forecast period.
  • Revenues from hospital-associated labs for colorectal cancer diagnostics are expected to reach nearly US$ 1,000 Mn by 2022-end. Independent diagnostic laboratories will continue to be the second most lucrative end-users in the global colorectal cancer diagnostics market.

Request Customization https://www.factmr.com/connectus/sample?flag=RC&rep_id=70

The report also includes a comprehensive landscape of global market for colorectal cancer diagnostics, where companies namely Illumina, Inc., Foundation Medicine, Inc., Sysmex Corporation, Cancer Genetics, Inc., Danaher Corporation, Biocept, Inc, Pathway Genomics Corporation, Rosetta Genomics, Epigenomics AG, and Exact Science Corporation are profiled.

Read More Trending and Similar Reports from Fact.MR – https://www.biospace.com/article/rapid-improvement-in-drug-delivery-technologies-fueling-the-demand-for-oral-thin-films-fact-mr/

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Categories
Pharmaceutical

Sales Of Colorectal Cancer Diagnostics Is Predicted To Rise 2.2x By The End Of The Decade

According to Fact.MR, a market research and competitive intelligence provider, the global colorectal cancer diagnostics market is anticipated to rise at a robust CAGR of 8.5% over the next ten years. As per this study, the market was valued at around US$ 2 Bn in 2020, and is anticipated to expand 2.2X by the end of the decade.

Incidence of colorectal cancer is increasing worldwide, and the World Health Organization (WHO) has predicted a rise of around 70% in cases by 2030. Increasing incidence of the disease can be attributed to factors such as poor lifestyle choices, unhealthy eating, aging, and diet-related disorders.

.

For detailed insights on enhancing your product footprint, request for a sample here- https://www.factmr.com/connectus/sample?flag=S&rep_id=70

The advent of new diagnostic tests, increasing uptakes of diagnosis-associated therapies, and initiatives taken by private as well as government organisations are some factors expected to propel growth of the global market for colorectal cancer diagnostics. Increasing unmet requirements across several emerging economies, coupled with the absence of neoadjuvant and adjuvant pipeline agents for diagnosing high-risk patients affected with resectable colorectal cancer is expected to create huge growth opportunities for leading players in the market. However, factors such as growing reluctance towards medications of colorectal cancer by patients, and unawareness across several remote regions of the globe is expected to inhibit the market growth.

6 Key Projections for the Global Colorectal Cancer Diagnostics Market

  • North America will continue to be the most lucrative region for the colorectal cancer diagnostics market. Revenue from market in North America is expected to surpass US$ 800 Mn by 2022-end.

For critical insights on this market, request for methodology here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=70

  • The colorectal cancer diagnostics market in Asia Pacific excluding Japan (APEJ) is expected to register the fastest expansion during the forecast period. However, revenue from the market in Middle East & Africa (MEA) will continue to be sluggish during the forecast period.
  • By test type, FOB will continue to be the largest adopted test for diagnosis of colorectal cancer across the globe. Revenue from FOB tests for colorectal cancer diagnostics will remain largest, followed by CTC tests.
  • Immunochemistry tests for colorectal cancer diagnostics will exhibit the highest CAGR through 2022. However, revenue from BRAF tests will remain the lowest in the global colorectal cancer diagnostics market during the forecast period.
  • On the basis of end-users, although hospital-associated labs will remain sought-after in the market, cancer research institutes will continue to register the fastest expansion during the forecast period.
  • Revenues from hospital-associated labs for colorectal cancer diagnostics are expected to reach nearly US$ 1,000 Mn by 2022-end. Independent diagnostic laboratories will continue to be the second most lucrative end-users in the global colorectal cancer diagnostics market.

Request Customization https://www.factmr.com/connectus/sample?flag=RC&rep_id=70

The report also includes a comprehensive landscape of global market for colorectal cancer diagnostics, where companies namely Illumina, Inc., Foundation Medicine, Inc., Sysmex Corporation, Cancer Genetics, Inc., Danaher Corporation, Biocept, Inc, Pathway Genomics Corporation, Rosetta Genomics, Epigenomics AG, and Exact Science Corporation are profiled.

Read More Trending and Similar Reports from Fact.MR – https://www.biospace.com/article/rapid-improvement-in-drug-delivery-technologies-fueling-the-demand-for-oral-thin-films-fact-mr/

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

Categories
Pharmaceutical

Demand for Colorectal Cancer Treatment is Anticipated to Hold its Position as a Dominant Shareholder in North America – Fact.MR Study

250 Pages Colorectal Cancer Treatment Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider

According to Fact MR’s recent market research, sales of Colorectal Cancer Treatment to swell at propelled CAGR through 2031, as investment towards expansion of healthcare infrastructure continues rising. The goal of the survey is uncover growth opportunities, key trends, growth drivers, and challenges. It also provides recommendations to assist businesses in preparing for unforeseen challenges.

Focus on improving overall patient care will remain a chief growth driver. Besides this, Colorectal Cancer Treatment market will continue gaining from increasing willingness among patients and families to spend on advanced healthcare.

To remain ‘ahead’ of your competitors, request for a sample –https://www.factmr.com/connectus/sample?flag=S&rep_id=70

Analysts at Fact.MR have recently updated the study on the global Colorectal Cancer Treatment market and have predicted to industry expansion at a CAGR of 8.5% over the decade. Fact.MR, a market research and competitive intelligence provider, has compiled a comprehensive assessment of various aspects that influence market growth and revenue potential. The market for Colorectal Cancer Treatment was worth US$ 2 Bn in 2020, and is predicted to rise 2.2X by the end of the decade.

Global Market Value in 2020 US$ 2 Bn
Projected Market Value for 2031 US$ 4.5 Bn
CAGR (2021-2031) 8.5%

The market study done by Fact.MR gives exclusive information about how the market will grow. The study identifies crucial trends that are determining the growth of Colorectal Cancer Treatment market. This newly published report sheds light on vital dynamics, such as the drivers, restraints, and opportunities for key market players as well as emerging players associated with the production and supply. The latest report by Fact.MR provides detailed Market Analysis of Colorectal Cancer Treatment

Colorectal cancer diagnostics market by Fact.MR

The report offers actionable and valuable market insights of Colorectal Cancer Treatment. The latest report by Fact.MR provides details on the present scenario of the market across various regions along with the historic data and forecast of the market. The report also includes information on the sales and demand of Colorectal Cancer Treatment Market across various industries and regions

Need more information about Report Methodology? Click here- https://www.factmr.com/connectus/sample?flag=RM&rep_id=70 

Key Segments Covered in Colorectal Cancer Treatment Industry Survey

  • By Test Type:

    • Colorectal Cancer FOB Tests
    • Colorectal Cancer CTC Tests
    • Colorectal Cancer CEA Tests
    • Colorectal Cancer BRAF V600 Mutation Tests
    • Colorectal Cancer Immunohistochemistry Tests
    • C-kit/CD117
    • KRAS Mutation Tests
    • Others
  • By End User:

    • Hospital-associated Labs
    • Independent Diagnostic Laboratories
    • Cancer Research Institutes
    • Others

Full Access of this Exclusive Report is Available at- https://www.factmr.com/checkout/70

Competitive Landscape

Providers of colorectal cancer diagnosis are investing in the research & development of devices and instruments that would aid in diagnosis and treatment more effectively and efficiently.

  • Researchers at the University of Warwick have developed a new deep learning algorithm that is capable of identifying molecular pathways and mutations that result in the development of colorectal cancer. This could be a breakthrough in treating colorectal cancer patients.
  • Research at the Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology has discovered a small molecule – RGX-202 – which, in future, could be administered along with therapy treatment to starve colorectal cancer metastasis.
  • Researchers at the Hollings Cancer Center are also studying the increasing incidence of colorectal cancer among young individuals and prevalence in minorities. This research could be crucial in controlling the prevalence of colorectal cancer and aid in providing better preventive diagnostic and treatment solutions.

6 Key Projections for the Global Colorectal Cancer Treatment Market

  1. North America will continue to be the most lucrative region for the Colorectal Cancer Treatment market. Revenue from market in North America is expected to surpass US$ 800 Mn by 2022-end.
  2. The Colorectal Cancer Treatment market in Asia Pacific excluding Japan (APEJ) is expected to register the fastest expansion during the forecast period. However, revenue from the market in Middle East & Africa (MEA) will continue to be sluggish during the forecast period.
  3. By test type, FOB will continue to be the largest adopted test for diagnosis of colorectal cancer across the globe. Revenue from FOB tests for Colorectal Cancer Treatment will remain largest, followed by CTC tests.
  4. Immunochemistry tests for Colorectal Cancer Treatment will exhibit the highest CAGR through 2022. However, revenue from BRAF tests will remain the lowest in the global Colorectal Cancer Treatment market during the forecast period.
  5. On the basis of end-users, although hospital-associated labs will remain sought-after in the market, cancer research institutes will continue to register the fastest expansion during the forecast period.
  6. Revenues from hospital-associated labs for Colorectal Cancer Treatment are expected to reach nearly US$ 1,000 Mn by 2022-end. Independent diagnostic laboratories will continue to be the second most lucrative end-users in the global Colorectal Cancer Treatment market.

Read More Trending Reports of Fact.MR-

https://www.biospace.com/article/demand-for-tricuspid-valve-repair-rising-as-congenital-and-rheumatoid-heart-disease-cases-increase-fact-mr/

Report Benefits & Key Questions Answered

  • Colorectal Cancer Treatment Category and segment level analysis: Fact MR provides a detailed analysis of the factors influencing sales growth across key segments. It highlights key growth drivers and provides useful information for identifying sales prospects at the regional and local level.
  • Colorectal Cancer Treatment Historical volume analysis: The report provides a comparison of Colorectal Cancer Treatment’s historical sales and projected sales performance for 2021-2031.
  • Colorectal Cancer Treatment Manufacturing trend analysis: The report offers a detailed analysis of manufacturing trends in the Colorectal Cancer Treatment market. It carefully gauges the impact of changing healthcare needs of key demographics globally
  • Colorectal Cancer Treatment Consumption by demographics: The report investigates consumer behavior affecting Colorectal Cancer Treatment demand outlook for the assessment period. Effect of their keenness for digital trends on Colorectal Cancer Treatment market is carefully analyzed
  • Post COVID consumer spending on Colorectal Cancer Treatment: Healthcare industry has been largely influenced by COVID-19 pandemic. The Fact MR Market survey analyzed consumer spending post COVID-19. It assesses how current trends that will influence expenditure on healthcare services, thus affecting Colorectal Cancer Treatment market growth.

More Valuable Insights on Colorectal Cancer Treatment Market

Fact.MR, in its new report, offers an unbiased Market Analysis of Colorectal Cancer Treatment, Sales and Demand of Colorectal Cancer Treatment, analyzing forecast statistics through 2019 and beyond. The study reveals growth projections on the basis of various criteria.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain:

Fluoro Enzymatic Assays Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Shower Chairs Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

Infrared Thermometer Market – Global Industry Analysis and Opportunity Assessment 2021 – 2031

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

 

Categories
Pharmaceutical

North America’s Demand for C-kit/CD117 Tests Is Anticipated to Account for Nearly US$ 800 Mn In Revenues by 2022-end

Big data and analytics will drive patient outcomes in a big way, and the coming years will witness a growing emphasis on healthcare service providers in the business of gathering and processing patient health data.

The global demand for colorectal cancer diagnostics is anticipated to exhibit an impressive expansion at a CAGR of 8.5% during the forecast period 2017 to 2022, according to a report by Fact.MR. Global revenues from the market are projected to surpass US$ 2,000 Mn by 2022-end.

For detailed insights on enhancing your product footprint, request for a sample here-
https://www.factmr.com/connectus/sample?flag=S&rep_id=70

Market Taxonomy

Test Type End User
FOB Hospital Associated Labs
CTC Tests Independent Diagnostic Laboratories
BRAF V600 Mutations Cancer Research Institutes
CEA Tests Others
C-kit/CD117
KRAS Mutation Tests
Immunohistochemistry
Others

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Speak to Research Analyst:
https://www.factmr.com/checkout/70

According to the World Cancer Research Fund, colorectal cancer forms the third-most occurring type of cancer across the globe. In 2012, over 1 Mn cases of colorectal cancer were diagnosed. Majority of these cases were reported across developed economies, and this is further estimated to exceed in the near future. This rise in incidences of colorectal cancer has boosted demand for its diagnostics, treatment, and therapeutics worldwide. However, the number of deaths owing to colorectal cancer has been witnessing a decline since recent past, owing to the awareness spread by the American Cancer Society. The introduction of more effective diagnostics, and development of screening methods are further expected to drive growth of the global colorectal cancer diagnostics market.

The advent of new diagnostic tests, increasing uptakes of diagnosis-associated therapies, and initiatives taken by private as well as government organisations are some factors expected to propel growth of the global market for colorectal cancer diagnostics. Increasing unmet requirements across several emerging economies, coupled with the absence of neoadjuvant and adjuvant pipeline agents for diagnosing high-risk patients affected with resectable colorectal cancer is expected to create huge growth opportunities for leading players in the market. However, factors such as growing reluctance towards medications of colorectal cancer by patients, and unawareness across several remote regions of the globe is expected to inhibit the market growth.

For More Insights:
https://www.biospace.com/article/increasing-demand-from-cosmetic-and-semiconductor-industries-is-shaping-growth-of-in-situ-particle-measurement-market-fact-mr/

6 Key Projections for the Global Colorectal Cancer Diagnostics Market

  1. North America will continue to be the most lucrative region for the colorectal cancer diagnostics market. Revenue from market in North America is expected to surpass US$ 800 Mn by 2022-end.
  2. The colorectal cancer diagnostics market in Asia Pacific excluding Japan (APEJ) is expected to register the fastest expansion during the forecast period. However, revenue from the market in Middle East & Africa (MEA) will continue to be sluggish during the forecast period.
  3. By test type, FOB will continue to be the largest adopted test for diagnosis of colorectal cancer across the globe. Revenue from FOB tests for colorectal cancer diagnostics will remain largest, followed by CTC tests.
  4. Immunochemistry tests for colorectal cancer diagnostics will exhibit the highest CAGR through 2022. However, revenue from BRAF tests will remain the lowest in the global colorectal cancer diagnostics market during the forecast period.
  5. On the basis of end-users, although hospital-associated labs will remain sought-after in the market, cancer research institutes will continue to register the fastest expansion during the forecast period.
  6. Revenues from hospital-associated labs for colorectal cancer diagnostics are expected to reach nearly US$ 1,000 Mn by 2022-end. Independent diagnostic laboratories will continue to be the second most lucrative end-users in the global colorectal cancer diagnostics market.

Need more information about Report Methodology? Click here-
https://www.factmr.com/connectus/sample?flag=RM&rep_id=70

The report also includes a comprehensive landscape of global market for colorectal cancer diagnostics, where companies namely

Illumina, Inc.
Foundation Medicine, Inc.
Sysmex Corporation
Cancer Genetics, Inc.
Danaher Corporation
Biocept, Inc
Pathway Genomics Corporation
Rosetta Genomics
Epigenomics AG
Exact Science Corporation

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com